Hayan Health Networks, Inc. has changed its corporate name to Boryung, Inc. as of 4/12/2022, and you will be forwarded to the new homepage for Boryung.com
About Us
Hayan Health Networks is a life science and healthcare investment and consulting company based in San Francisco, incorporated as the corporate venture arm of Boryung Holding.
Hayan invests in innovation to find new, effective ways to target difficult-to-treat diseases and address current medical unmet needs. By supporting early stage research and development via investments and partnerships, we hope to be a part of innovation in life science and healthcare.
AUM
FOCUS
$50M
since 2019
Innovative, next generation technologies
Oncology, rare diseases, chronic diseases
Other areas with medical unmet needs
Hayan is the corporate venture arm of Boryung Holdings, and investment and management company headquartered in S. Korea. Boryung Holdings has $500M assets under management and is controlling three healthcare companies: Boryung Pharmaceutical, Boryung Biopharma and Boryung Consumer.
Team
Peter Choi
Chief Executive Officer
Mr. Peter Choi serves as the Chief Executive Officer at Hayan Health Networks since its founding. He is also serving a dual role as the Senior Vice President & the Head of Acquisitions & Business Development at Boryung Holdings. He focuses on legacy asset & brand acquisitions and other global business & scientific collaborations. He has over 20 years of experience in pharmaceutical industries, including business development, licensing, commercialization & market access, technology transfer, strategic partnerships, and departmental operations & management. Read more
JP (Jung-Hwan) Shim
Chief Strategy Officer
Mr. JP Shim currently serves as the Vice President, Chief Strategy Officer at Hayan Health Networks, while serving a dual role as the A&BD Strategy Lead at Boryung Holdings. With strong industry expertise in life science and healthcare sectors, JP has been responsible for identifying legacy brand acquisition opportunities and managing their commercial assessments. He has over 18 years of experiences in the industry, including 15 years in Pfizer APAC Region and Pfizer Korea. Read more
Partners
![shutterstock_108300506-[변환됨].jpg](https://static.wixstatic.com/media/44a3a8_8bc6360c94eb48bea0880dcdb348fc96~mv2.jpg/v1/fill/w_1070,h_580,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/shutterstock_108300506-%5B%EB%B3%80%ED%99%98%EB%90%A8%5D.jpg)
Boston, USA
Investment Partners
Israel
Investment Partners
Singapore
Regional Strategic Partner
Japan
Regional Strategic Partners
Korea
Boryung Pharma Group
Investment Partners
Toronto, Canada
Investment Partners
San Francisco, USA
Investment Partners
Portfolio
Global Life Science
PE Fund
Investment: 2019
Global Life Science
VC Fund
Investment: TBA
Korean Life Science
VC Fund
Investment: 2019
Global top private equity fund with differentiated investment models focused on assets in late stage development
Global venture capital fund with proprietary investment platform targeting emerging biotech companies
Korean venture capital fund investing into early stage biotech companies in Korea and the US
Investment: 2020
Investment: 2020
Investment: 2020
Investment: 2020
Clinical stage biotech company developing first-in-class biologics for NASH and other fibrosis-related diseases
Biotech company developing best-in-class therapeutic antibodies with ML-based antibody discovery platform
Emerging biotech company with proprietary discovery and ML platform to identify novel targets and TCRs
Biotech company developing adoptive cell therapies with prioprietry next generation CAR-T technology